BioAffinity Technologies Secures New Canadian Patent for CyPath® Lung, Its Noninvasive Lung Cancer Test
A biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company’s commercially available test for early-stage lung cancer, today announced its patent related to a method to detect lung disease…
